Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
NCT ID: NCT01433237
Last Updated: 2016-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2011-09-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
NCT01365962
Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma
NCT01585376
Biomarkers in Patients With Rhabdomyosarcoma
NCT01466283
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma
NCT01496573
Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma
NCT01609803
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine whether circulating muscle-specific microRNAs, especially serum miR-206, are potential biomarkers for rhabdomyosarcoma (RMS).
OUTLINE: Archived serum samples are analyzed for miR-206 expression.
PROJECTED ACCRUAL: A total of 15 samples from patients with alveolar rhabdomyosarcoma (RMS), 15 from patients with embryonal RMS, and 10 from patients without RMS will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RNA analysis
gene expression analysis
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serum specimens of rhabdomyosarcoma (RMS), embryonal RMS, and non-RMS available from the Soft Tissue Sarcoma committee of Children's Oncology Group
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hajime Hosoi, MD
Role: PRINCIPAL_INVESTIGATOR
Kyoto Prefectural University of Medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ARST12B1
Identifier Type: OTHER
Identifier Source: secondary_id
ARST12B1
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-03457
Identifier Type: REGISTRY
Identifier Source: secondary_id
ARST12B1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.